Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-26. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Lucas, the youngest Marine to receive the Medal of Honor, who then re-enlisted and became a Captain in the 82nd Senator Dave McCormick (born 1965), Captain who served in the Gulf War Wes Moore, 63rd governor of Maryland Platoon Forward Observer and Member of USA National Bobsled Team Lou Moreira Country music singer Craig Morgan (born 1964) Patrick Murphy, Under Secretary of the Army (born 1973) Actor Noble Craig, Vietnam War R&B singer Lou Rawls Sergeant in B Co 2/505 ABN INF 1956–58 Senator Jack Reed (born 1949) Dennis Richmond, journalist Syracuse University football coach Ben Schwartzwalder General "Henry" Hugh Shelton (Chairman of the Joint Chiefs of Staff from 1997 to 2001) Private John Steele who famously got hung up on a parapet of the church bell tower when jumping into Sainte-Mère-Église during the first hours of D-Day. Senator Strom Thurmond (325th Glider Infantry Regiment in World War II) Actor William Windom Colonel Benjamin H. Vandervoort who led the 2nd Battalion, 505th PIR on D-Day and the 3rd Battalion, 504th PIR during Operation Market Garden. Sergeant Alvin C. York (Medal of Honor recipient), World War I Trae Stewart Spurlock a 2x combat veteran killed by the Casper Police Department James Megellas One of the most decorated veterans of the 82nd
The traditional view of cephalopod evolution holds that they evolved in the Late Cambrian from a monoplacophoran-like ancestor with a curved, tapering shell, which was closely related to the gastropods (snails). The similarity of the early shelled cephalopod Plectronoceras to some gastropods was used in support of this view. The development of a siphuncle would have allowed the shells of these early forms to become gas-filled (thus buoyant) in order to support them and keep the shells upright while the animal crawled along the floor, and separated the true cephalopods from putative ancestors such as Knightoconus, which lacked a siphuncle. Neutral or positive buoyancy (i.e. the ability to float) would have come later, followed by swimming in the Plectronocerida and eventually jet propulsion in more derived cephalopods. Possible early Cambrian remains have been found in the Avalon Peninsula, matching genetic data for a pre-Cambrian origin. However, this specimen is later shown that is a chimerical fossil. In 2010, some researchers proposed that Nectocaris pteryx is the earliest cephalopod, which did not have a shell and appeared to possess jet propulsion in the manner of "derived" cephalopods, complicated the question of the order in which cephalopod features developed. However, most other researchers doubt that Nectocaris was actually a cephalopod or even a mollusk, and in 2025 a study found it to be a relative of modern chaetognaths (arrow worms).
A GFD involves removing all food and drink that contains wheat, rye, barley, and gluten derivatives. Coeliac disease symptoms can improve within days of adopting a GFD, and the diet improves quality of life, prevents further complications, and can normalise some effects of the disease such as stunted growth. The GFD can be difficult, requiring significant education and motivation. Additionally, the GFD diet may lead to nutritional deficiencies due to difficulties accessing nutritionally balanced gluten-free food. As such, a referral to a dietitian is recommended by treatment guidelines. A dietitian can help those with coeliac disease identify gluten-containing food and maintain a nutritionally balanced diet. The exact amount of gluten that may be tolerable for those with coeliac disease varies, with some people able to consume around 35 mg per day without damage to the intestines, while others can not tolerate more than 10 mg a day. Currently, international regulatory agencies require a product to contain less than 20 ppm (about 6 mg per day) of gluten to be labelled as gluten-free.
== Research == A major focus of his research is analytical separations theory and its application. His research group develops analytical techniques for molecular recognition and molecularly selective microextractions, and utilizes “green” separation procedures using aqueous solutions and nonvolatile polymeric systems. They have developed thin films for solid-phase micro extraction (SPME). Weber develops electrochemical detectors for use with liquid chromatography techniques. An important area of application is the identification of peptides, which help to control the body. Some of the systems which neuropeptides influence include pain, mood, social and emotional behavior, responses to stress, and memory. Understanding how peptides affect neurochemistry and other biological systems has important implications for medicine and pharmaceutical development. Dipeptides can be present in the brain at sub-picomole levels. To work effectively at this level, techniques must be highly sensitive and selective. Weber and his colleagues work on techniques to sample minute quantities from brain fluid and from single living cells. They are developing specialized sampling protocols with the goal of obtaining minute amounts of material from living organisms with minimal damage.
Sources: en.wikipedia.org
==== Infrastructure ==== The conflict resulted in widespread destruction in Lebanon that was particularly seen in the south, east, and Dahieh—the southern suburbs of the capital, Beirut. According to the World Bank, 99,209 houses were damaged during the conflict, of which 18% were destroyed. By 31 October 2024, nearly 25% of the buildings in towns near the border were damaged or destroyed, with the most destruction occurring in Kfar Kila and Ayta ash-Shaab. Roughly 80% of the damage occurred after 2 October. In the areas that the IDF had captured during its ground invasion into Lebanon, 42% of buildings were destroyed, according to NBC News. Amnesty International reported the damaging or destruction of over 10,000 buildings between October 2024 and January 2025, with 70% of the buildings in Yaroun, Dhayra, and Al-Bustan being severely damaged or destroyed. UN-Habitat reported that 27% of buildings in Marjayoun and 15% of buildings in Bint Jbeil were damaged or destroyed, while the mayor of Kfar Kila stated that 90% of the homes in the village were destroyed during the conflict, with the remaining 10% sustaining damage. The scale of destruction in Dahieh was comparable to the 2006 Lebanon war, with 353 buildings in the area being destroyed and more than 6,000 houses damaged. The Hezbollah-linked newspaper Al Akhbar reported that the cost of damages in Dahieh was $630 million. More than 60 schools have been destroyed since September 2024, according to Save the Children.
Subject of research: synthesis of organophosphorous and organoelement compounds, study of their spatial and electronic structure, intramolecular electronic interactions, reaction capacity and mechanism of reactions. Arkady N. Pudovik corresponding member of Russian Academy of Science worked at this department since its opening (1948) until his death (February 2006) he was the founder of the department of High Molecular and Organoelement Compounds and held the position of Head of department until 1987. Current head of the Department – Corresponding Member of the Academy of Sciences of the Republic of Tatarstan, Professor Vladimir I. Galkin, doctor of Science in chemistry. The Department conducts research in the following fields:
Counter-Strike (CS) is a series of multiplayer tactical first-person shooter video games, in which opposing teams attempt to complete various objectives. The series began on Windows in 1999 with the release of the first game, Counter-Strike. It was initially released as a mod for Half-Life that was designed by Minh Le and Jess Cliffe before the rights to the mod's intellectual property were acquired by Valve, the developers of Half-Life, who then turned Counter-Strike into a retail product released in 2000. The original Counter-Strike was followed by Counter-Strike: Condition Zero, developed by Turtle Rock Studios and released in March 2004. A previous version of Condition Zero that was developed by Ritual Entertainment was released alongside it as Condition Zero: Deleted Scenes. Eight months later, Valve released Counter-Strike: Source, a remake of the original Counter-Strike and the first in the series to run on Valve's then-newly created Source engine. The fourth game in the main series, Counter-Strike: Global Offensive, was released by Valve in 2012 for Windows, OS X, Xbox 360, and PlayStation 3. Hidden Path Entertainment, who worked on Counter-Strike: Source post-release, helped to develop the game alongside Valve. Counter-Strike 2 was announced in March 2023 and publicly released on September 27, 2023, as a replacement for Global Offensive. There have been several third-party spin-off titles created for Asian markets over the years. These include the Counter-Strike Online series, Counter-Strike Neo, and Counter-Strike Nexon: Studio.
Sources: en.wikipedia.org
== Applications == Charged surfaces are extremely important and are used in many applications. For example, solutions of large colloidal particles depend almost entirely on repulsion due to surface charge in order to stay dispersed. If these repulsive forces were to be disrupted, perhaps by the addition of a salt or a polymer, the colloidal particles would no longer be able to sustain suspension and would subsequently flocculate.
=== Signal transduction to the nucleus === PLCγ is a very important enzyme in the pathway as it generates second messenger molecules. It is activated by the tyrosine kinase Itk which is recruited to the cell membrane by binding to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 is produced by the action of phosphoinositide 3-kinase(PI-3K), which phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to produce PIP3. It is not known that PI-3K is activated by the T-cell receptor itself, but there is evidence that CD28, a co-stimulatory receptor providing the second signal, is able to activate PI-3K. The interaction between PLCγ, Itk and PI-3K could be the point in the pathway where the first and the second signal are integrated. Only if both signals are present, PLCγ is activated. Once PLCγ is activated by phosphorylation. It hydrolyses PIP2 into two secondary messenger molecules, namely the membrane-bound diacyl glycerol (DAG) and the soluble inositol 1,4,5-trisphosphate (IP3). These second messenger molecules amplify the TCR signal and distribute the prior localized activation to the entire cell and activate protein cascades that finally lead to the activation of transcription factors. Transcription factors involved in T-cell signaling pathway are the NFAT, NF-κB and AP1, a heterodimer of proteins Fos and Jun. All three transcription factors are needed to activate the transcription of interleukin-2 (IL2) gene.
=== Specialized === Laboratory tests (e.g. Erythrocyte Sedimentation Rate, Rheumatoid Factor, Anti-CCP (Anti-citrullinated protein antibody), ANA (Anti-Nuclear Antibody) ) X-rays, Ultrasounds, and other imaging methods of affected joints Cytopathology and chemical pathology of fluid aspirated from affected joints (e.g. to differentiate between septic arthritis and gout)
Other advantages of the NPT approach are that it is fast and convenient, usually less painful, and offers, in home use, the ability for patients to measure their own INRs when required. Among its problems are that quite a steady hand is needed to deliver the blood to the exact spot, that some patients find the finger-pricking difficult, and that the cost of the test strips must also be taken into account. In the UK these are available on prescription so that elderly and unwaged people will not pay for them and others will pay only a standard prescription charge, which at the moment represents only about 20% of the retail price of the strips. In the US, NPT in the home is currently reimbursed by Medicare for patients with mechanical heart valves, while private insurers may cover for other indications. Medicare is now covering home testing for patients with chronic atrial fibrillation. Home testing requires a doctor's prescription and that the meter and supplies are obtained from a Medicare-approved Independent Diagnostic Testing Facility (IDTF). There is some evidence to suggest that NPT may be less accurate for certain patients, for example those who have the lupus anticoagulant.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.